Page 16 - Dyslipidaemia_newsletter8_2024_Final

REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #8 2024

CONFERENCE CORNER Dyslipidaemia

The ESC Congress, hosted in London, England on Aug 30th– 2nd Sept 2nd 2024, is the annual meeting
of the European Society of Cardiology. We present below some abstracts of interest that may have an
impact on clinical practice. Please click on the links to explore the abstracts, or where available, the
presentations in more detail.

LIPIDS AS RISK FACTORS FOR HEART DISEASE

1. Low-density lipoprotein cholesterol goal attainment with “inclisiran first” versus usual care in patients with
atherosclerotic cardiovascular disease. Rodriguez F, et al. Eur Heart J, Vol 45 (Suppl 1): ehae666.2867

DYSLIPIDAEMIA: NOVEL DIAGNOSTICS AND THERAPY OPTIONS

2. Comparative efficacy of colchicine and intensive LDL-C lowering in patients with ASCVD receiving statins: A
network meta-analysis of randomised controlled trials. Ou Z, et al. Eur Heart J, Vol 45 (Suppl 1): ehae666.2785

3. The upfront lipid-lowering combination therapy of statins and ezetimibe vs statin monotherapy in the reduction of
cardiovascular outcomes. A meta-analysis. Banach M, et al. Eur Heart J, Vol 45 (Suppl 1): ehae666.2873

4. Contemporary LDL-cholesterol management in male and female patients at high-cardiovascular risk: results from
the European observational SANTORINI study. Nanchen D, et al. Eur Heart J, Vol 45 (Suppl 1): ehae666.2631

LIPID-LOWERING THERAPY: STATINS AND BEYOND

5. Efficacy and safety of inclisiran in real-world clinical practice. Results from the CHOLINET Registry. Gargiulo P, et al.
Eur Heart J, Vol 45 (Suppl 1): ehae666.3299

6. Efficacy of combination lipid lowering therapy in achieving low density lipoprotein cholesterol targets after
one month of event in patients with acute coronary syndrome. Mahajan K, et al. Eur Heart J, Vol 45 (Suppl 1):
ehae666.3298

REGISTRIES, OBSERVATIONAL, AND OTHER STUDIES ON LIPIDS

7. Association of early versus late use of combination lipid-lowering therapy with major cardiovascular outcomes
after myocardial infarction: data from the SWEDEHEART registry. Leosdottir M, et al. Presented Sept 1, 2024 at the
ESC Conference

LIPID-LOWERING DRUGS: NEW INSIGHTS

8. Combination of moderate-intensity statins and ezetimibe versus high-intensity statins alone for primary prevention
of cardiovascular events. Godoy LC, et al. Eur Heart J, Vol 45 (Suppl 1): ehae666.2861

9. Safety and efficacy of moderate-intensity statin plus ezetimibe versus high-intensity statin monotherapy in patients
with atherosclerotic cardiovascular disease: A meta-analysis. Alves Kelly F, et al. Eur Heart J, Vol 45 (Suppl 1):
ehae666.2871

TABLE OF CONTENTS